Physician profile
Samuel Licata
NPI 1710973870
$21,773.41
in general payments reported to CMS, 2019-2025
41 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $1,010 · 2021: $344 · 2022: $269 · 2023: $231 · 2024: $1,320 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $16K · Food and Beverage: $2,077 · Travel and Lodging: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $16,000.00 |
| Food and Beverage | $2,077.12 |
| Travel and Lodging | $1,370.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $19,109.43 | 2019-2025 | Da Vinci Surgical System |
| Smith+Nephew, INC. | $387.92 | 2019-2025 | Collagenase Santyl, Stravix Pl, Renasys Go V2 Home |
| W. L. Gore & Associates, INC. | $262.06 | 2019-2024 | Gore Synecor Biomaterial |
| Musculoskeletal Transplant Foundation INC. | $248.97 | 2019-2021 | |
| Medtronic USA, INC. | $178.87 | 2019-2020 | |
| Astellas Pharma US INC | $145.47 | 2019-2025 | Xtandi |
| Eisai INC. | $116.40 | 2019-2025 | |
| Incyte Corporation | $114.14 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Phathom Pharmaceuticals, INC. | $106.29 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $91.30 | 2019-2025 | |
| Hologic INC | $75.33 | 2021 | |
| Tela Bio, INC. | $66.59 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $64.10 | 2019-2025 | Echelon; Endopath, Harmonic, Echelon Circular |
| Regeneron Healthcare Solutions, INC. | $59.20 | 2022-2025 | Lynozyfic |
| Baxter Healthcare | $49.99 | 2024-2025 | Tisseel, Floseal |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.40 | 2024-2025 | Jaypirca, Retevmo, Verzenio |
| Organogenesis INC. | $46.47 | 2019-2023 | Puraply |
| Exelixis INC. | $44.88 | 2022-2025 | Cabometyx |
| Braintree Laboratories, INC. | $43.45 | 2021-2022 | |
| Emd Serono, INC. | $43.27 | 2022-2024 | |
| Davol INC. | $42.83 | 2019 | |
| Surgenex LLC | $30.57 | 2025 | Surmatrix, Pellograft, Ardeograft |
| Abbvie INC. | $29.42 | 2025 | |
| Daiichi Sankyo INC. | $28.91 | 2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $27.40 | 2025 | |
| Molli Surgical (US) INC | $25.74 | 2022 | |
| Morphosys, US INC. | $22.45 | 2023 | Monjuvi |
| Seagen INC. | $21.98 | 2023 | Padcev |
| Clovis Oncology, INC. | $21.87 | 2019 | |
| Merck Sharp & Dohme LLC | $21.45 | 2024 | Keytruda |
| Merz North America, INC. | $20.12 | 2024 | |
| Abbott Laboratories | $19.99 | 2021 | |
| Tesaro, INC. | $19.78 | 2019 | |
| Solventum Corporation | $19.63 | 2025 | Prevena, V.A.C.Ulta |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2020 | |
| Bioptics, INC. | $18.38 | 2019 | |
| Amgen INC. | $18.24 | 2023 | Vectibix, Xgeva, Nplate |
| Ge Healthcare | $17.76 | 2022 | |
| Access Pro Medical, LLC | $15.52 | 2023 | Matriderm |
| Foundation Medicine, INC. | $15.41 | 2020 | |
| Cti Biopharma Corp. | $14.72 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Licata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.